Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bern-Thomas Nyang'wa

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
BMJ Open|September 7, 2021
Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PROBeverley Stringer, Karen Lowton, Nicola James, et al.
Lancet (London, England)|February 27, 2013
Resistance to second-line drugs in multidrug-resistant tuberculosisBern-Thomas Nyang'wa, Grania Brigden, Philipp du Cros, et al.
Lancet (London, England)|July 30, 2019
Multidrug-resistant tuberculosisBern-Thomas Nyang'wa, Catherine Berry, Katherine Fielding, et al.
Bulletin of the World Health Organization|January 25, 2012
Counting children: comparing reporting for paediatric HIV and tuberculosisPhilipp du Cros, Bern-Thomas Nyang'wa, Marianne Gale, et al.
PLOS Global Public Health|March 24, 2023
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosisSedona Sweeney, Catherine Berry, Emil Kazounis, et al.
BMJ Open|September 7, 2021
Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trialBern-Thomas Nyang'wa, Frank Kloprogge, David A J Moore, et al.
PLOS Global Public Health|April 23, 2025
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimensDzintars Gotham, Manuel Martin, Melissa J Barber, et al.
Plos One|May 1, 2012
Association of BMI category change with TB treatment mortality in HIV-positive smear-negative and extrapulmonary TB patients in Myanmar and ZimbabweLenka Benova, Katherine Fielding, Jane Greig, et al.
Nature Communications|June 10, 2026
Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatmentBern-Thomas Nyang'wa, Ilaria Motta, Ronelle Moodliar, et al.
PLOS Global Public Health|September 24, 2024
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohortJocelyn Jansen van Vuuren, Tim Crocker-Buque, Catherine Berry, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
BMJ Open|September 7, 2021
Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PROBeverley Stringer, Karen Lowton, Nicola James, et al.
Lancet (London, England)|February 27, 2013
Resistance to second-line drugs in multidrug-resistant tuberculosisBern-Thomas Nyang'wa, Grania Brigden, Philipp du Cros, et al.
Lancet (London, England)|July 30, 2019
Multidrug-resistant tuberculosisBern-Thomas Nyang'wa, Catherine Berry, Katherine Fielding, et al.
Bulletin of the World Health Organization|January 25, 2012
Counting children: comparing reporting for paediatric HIV and tuberculosisPhilipp du Cros, Bern-Thomas Nyang'wa, Marianne Gale, et al.
PLOS Global Public Health|March 24, 2023
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosisSedona Sweeney, Catherine Berry, Emil Kazounis, et al.
BMJ Open|September 7, 2021
Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trialBern-Thomas Nyang'wa, Frank Kloprogge, David A J Moore, et al.
PLOS Global Public Health|April 23, 2025
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimensDzintars Gotham, Manuel Martin, Melissa J Barber, et al.
Plos One|May 1, 2012
Association of BMI category change with TB treatment mortality in HIV-positive smear-negative and extrapulmonary TB patients in Myanmar and ZimbabweLenka Benova, Katherine Fielding, Jane Greig, et al.
Nature Communications|June 10, 2026
Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatmentBern-Thomas Nyang'wa, Ilaria Motta, Ronelle Moodliar, et al.
PLOS Global Public Health|September 24, 2024
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohortJocelyn Jansen van Vuuren, Tim Crocker-Buque, Catherine Berry, et al.
Pageof 3